Biotech · Public company · New York, NY, US

Axsome Therapeutics, Inc.

Ticker AXSM · SEC CIK 0001579428

Track this companyFree. Adds Axsome Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials2513 recruiting or active

Pipeline programs27From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline27

AXS-05Phase 3 · Agitation in Patients With Dementia of the Alzheimer's TypeClinicalTrials.gov · fetched Nov 12, 2026
AXS-05 (dextromethorphan-bupropion)Phase 3 · Smoking CessationClinicalTrials.gov · fetched Nov 12, 2026
AXS-05 (dextromethorphan-bupropion)Phase 3 · Agitation in Patients With Dementia of the Alzheimer's TypeClinicalTrials.gov · fetched Nov 12, 2026
AXS-07 (meloxicam-rizatriptan)Phase 3 · MigraineClinicalTrials.gov · fetched Nov 12, 2026
AXS-07 (MoSEIC meloxicam and rizatriptan)Phase 3 · MigraineClinicalTrials.gov · fetched Nov 12, 2026
AXS-12 (reboxetine)Phase 3 · NarcolepsyClinicalTrials.gov · fetched Nov 12, 2026
AXS-14 (Esreboxetine)Phase 3 · FibromyalgiaClinicalTrials.gov · fetched Nov 12, 2026
BupropionPhase 3 · Smoking CessationClinicalTrials.gov · fetched Nov 12, 2026
SolriamfetolPhase 3 · ADHDClinicalTrials.gov · fetched Nov 12, 2026
SolriamfetolPhase 3 · Binge-Eating DisorderClinicalTrials.gov · fetched Nov 12, 2026
Solriamfetol 150 mgPhase 3 · ADHDClinicalTrials.gov · fetched Nov 12, 2026
Solriamfetol 150 mgPhase 3 · Binge-Eating DisorderClinicalTrials.gov · fetched Nov 12, 2026
Solriamfetol 150 mgPhase 3 · Excessive SleepinessClinicalTrials.gov · fetched Nov 12, 2026
Solriamfetol 150 MGPhase 3 · Major Depressive Disorder With Excessive Daytime Sleepiness SymptomsClinicalTrials.gov · fetched Nov 12, 2026
Solriamfetol 300 mgPhase 3 · Binge-Eating DisorderClinicalTrials.gov · fetched Nov 12, 2026
Solriamfetol 300 mgPhase 3 · Major Depressive DisorderClinicalTrials.gov · fetched Nov 12, 2026
Solriamfetol 300 mgPhase 3 · Excessive SleepinessClinicalTrials.gov · fetched Nov 12, 2026
Solriamfetol 300 mgPhase 3 · ADHDClinicalTrials.gov · fetched Nov 12, 2026
Solriamfetol Dose APhase 3 · ADHDClinicalTrials.gov · fetched Nov 12, 2026
Solriamfetol Dose BPhase 3 · ADHDClinicalTrials.gov · fetched Nov 12, 2026
AXS-05 (dextromethorphan-bupropion)Phase 2 · Treatment Resistant DepressionClinicalTrials.gov · fetched Nov 12, 2026
AXS-05Major Depressive DisorderClinicalTrials.gov · fetched Nov 12, 2026
BupropionMajor Depressive DisorderClinicalTrials.gov · fetched Nov 12, 2026
No treatmentNarcolepsyClinicalTrials.gov · fetched Nov 12, 2026
Other prescription wake-promoting medications or stimulantsNarcolepsyClinicalTrials.gov · fetched Nov 12, 2026
SolriamfetolExcessive Daytime SleepinessClinicalTrials.gov · fetched Nov 12, 2026
Sunosi (solriamfetol)NarcolepsyClinicalTrials.gov · fetched Nov 12, 2026

Clinical trials25

Studying NMDA and Sigma-1 in Smoking Cessation Treatment (SUMMIT)PHASE3 · RECRUITING · started Aug 27, 2026ClinicalTrials.gov NCT07766655 · fetched Nov 12, 2026
An Open-Label Study to Assess the Long-Term Safety of Solriamfetol in Children and Adolescents With ADHDPHASE3 · ENROLLING_BY_INVITATION · started Aug 6, 2026ClinicalTrials.gov NCT07773883 · fetched Nov 12, 2026
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)PHASE3 · RECRUITING · started Jul 6, 2026ClinicalTrials.gov NCT07717879 · fetched Nov 12, 2026
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)PHASE3 · RECRUITING · started Jun 25, 2026ClinicalTrials.gov NCT07717892 · fetched Nov 12, 2026
Open-Label Safety Study of AXS-14 in Subjects With FibromyalgiaPHASE3 · ENROLLING_BY_INVITATION · started Apr 29, 2026ClinicalTrials.gov NCT07637162 · fetched Nov 12, 2026
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using SolriamfetolPHASE3 · RECRUITING · started Feb 23, 2026ClinicalTrials.gov NCT07484217 · fetched Nov 12, 2026
Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research DesignPHASE3 · RECRUITING · started Jan 14, 2026ClinicalTrials.gov NCT07398417 · fetched Nov 12, 2026
A Study to Assess the Long-term Safety and Efficacy of Solriamfetol in Subjects With Binge Eating DisorderPHASE3 · ENROLLING_BY_INVITATION · started Feb 20, 2025ClinicalTrials.gov NCT06878976 · fetched Nov 12, 2026
An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension StudyPHASE3 · TERMINATED · started Nov 21, 2024ClinicalTrials.gov NCT06736509 · fetched Nov 12, 2026
Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)PHASE3 · RECRUITING · started Aug 1, 2024ClinicalTrials.gov NCT06568367 · fetched Nov 12, 2026
Solriamfetol for the Treatment of Multiple Sclerosis FatiguePHASE2 · RECRUITING · started Jun 1, 2024ClinicalTrials.gov NCT06170970 · fetched Nov 12, 2026
Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using SolriamfetolPHASE3 · RECRUITING · started Apr 26, 2024ClinicalTrials.gov NCT06413433 · fetched Nov 12, 2026
Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using SolriamfetolPHASE3 · COMPLETED · started Mar 18, 2024ClinicalTrials.gov NCT06360419 · fetched Nov 12, 2026
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive SymptomsPHASE4 · RECRUITING · started Dec 27, 2023ClinicalTrials.gov NCT06223880 · fetched Nov 12, 2026
Solriamfetol and CBT-I in Patients With Insomnia DisorderPHASE4 · COMPLETED · started Jul 31, 2023ClinicalTrials.gov NCT05838430 · fetched Nov 12, 2026
A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)PHASE3 · COMPLETED · started Jul 6, 2023ClinicalTrials.gov NCT05972044 · fetched Nov 12, 2026
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease AgitationPHASE3 · COMPLETED · started Sep 6, 2022ClinicalTrials.gov NCT05557409 · fetched Nov 12, 2026
Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE)PHASE3 · COMPLETED · started Aug 31, 2022ClinicalTrials.gov NCT05550207 · fetched Nov 12, 2026
A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With NarcolepsyPHASE3 · COMPLETED · started Sep 15, 2021ClinicalTrials.gov NCT05059223 · fetched Nov 12, 2026
A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease AgitationPHASE3 · COMPLETED · started Jun 17, 2021ClinicalTrials.gov NCT04947553 · fetched Nov 12, 2026
Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled StudyPHASE4 · COMPLETED · started May 17, 2021ClinicalTrials.gov NCT04789174 · fetched Nov 12, 2026
Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)PHASE2 · TERMINATED · started Sep 23, 2020ClinicalTrials.gov NCT04634669 · fetched Nov 12, 2026
Initiating Early Control of Migraine Pain and Associated SymptomsPHASE3 · COMPLETED · started Oct 8, 2019ClinicalTrials.gov NCT04163185 · fetched Nov 12, 2026
SUNOSI® (Solriamfetol) Pregnancy RegistryRECRUITING · started Jul 31, 2019ClinicalTrials.gov NCT06413420 · fetched Nov 12, 2026
Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT)PHASE2 · COMPLETED · started Apr 5, 2019ClinicalTrials.gov NCT03881852 · fetched Nov 12, 2026

SEC filings12

10-Q · 10-QSEC EDGAR · filed Nov 2, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Nov 2, 2026 · fetched Nov 12, 2026
10-Q · 10-QSEC EDGAR · filed Aug 10, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Aug 10, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Jul 15, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Jun 9, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Jun 9, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Jun 3, 2026 · fetched Nov 12, 2026
10-Q · 10-QSEC EDGAR · filed May 4, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed May 4, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Apr 30, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Apr 1, 2026 · fetched Nov 12, 2026